BioLineRx Ltd. (TLV:BLRX)
1.500
0.00 (0.00%)
At close: Mar 13, 2026
BioLineRx Revenue
BioLineRx had revenue of $427.00K USD in the quarter ending September 30, 2025, a decrease of -91.36%. This brings the company's revenue in the last twelve months to $12.74M, down -42.09% year-over-year. In the year 2024, BioLineRx had annual revenue of $28.94M with 502.92% growth.
Revenue (ttm)
$12.74M
Revenue Growth
-42.09%
P/S Ratio
0.93
Revenue / Employee
$454.82K
Employees
28
Market Cap
39.16M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.94M | 24.14M | 502.92% |
| Dec 31, 2023 | 4.80M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 12.28M |
| XTL Biopharmaceuticals | 3.26M |
| Can-Fite BioPharma | 1.89M |
| Clal Biotechnology Industries | 91.00K |
| Geffen Residence & Renewal | 84.00K |
| BioLight Life Sciences | 21.00K |
BioLineRx News
- 3 months ago - BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall - GuruFocus
- 3 months ago - BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture - GuruFocus
- 3 months ago - BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Earnings Scheduled For November 24, 2025 - Benzinga
- 4 months ago - BioLine Rx's Earnings: A Preview - Benzinga
- 4 months ago - BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 - PRNewsWire
- 4 months ago - BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types - PRNewsWire